What is Urology?
Urology of Central PA (UCPA) is at the forefront of providing innovative solutions for patients suffering from incontinence and related conditions. Leveraging advancements in sacral neuromodulation (SNM) therapy, particularly Medtronic's InterStim technology, UCPA physicians are enhancing patient quality of life. The recent FDA approval of the InterStim Micro neurostimulator and InterStim SureScan MRI leads marks a significant technological leap, offering smaller, rechargeable, and MRI-compatible devices. This expansion in therapeutic options, including treatments for overactive bladder (OAB) and fecal incontinence (FI), positions Urology as a key player in patient-centric urological care.
How much funding has Urology raised?
Urology has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for Urology?
The substantial enterprise-level funding and major strategic investment indicate a phase of significant scaling and technological integration for Urology. Future developments are likely to focus on expanding the reach of their advanced SNM therapies, further research into neuromodulation applications, and potentially broader market penetration. The company's commitment to adopting and deploying the latest FDA-approved technologies suggests a strategic roadmap centered on innovation and patient outcomes, aiming to solidify its leadership in the urology and incontinence treatment market.
See full Urology company page
